Current Studies
Trailblazer Alzheimer's Study - Healthy Volunteers
The Trailblazer Alzheimer’s Study involves people who have normal memory, thinking, mood and behavior patterns. Participants are randomly assigned to one of two groups. They receive either the investigational drug or a placebo. Those who receive placebo may have the option to receive the investigational drug at a later time.
This study might be right for you if you are:
- 55 to 80 years of age
- Having normal memory, thinking, mood and behavior patterns
- Able to have a reliable study partner* who knows you and is willing to attend appointments with you throughout the study
- Able to meet additional study requirements
AVP Alzheimer’s Study - The ASPECT Study
The ASPECT Study will look at an investigational medication for people with Alzheimer’s Disease. The purpose of this study is to evaluate the safety and effectiveness of an investigational drug for agitation associated with Alzheimer’s Dementia.
This study might be right for you if you are:
- Between the ages of 50 and 90
- Having a diagnosis of probable Alzheimer’s disease
- Having moderate-to-severe agitation that interferes with daily life
- Able to have a caregiver who spends a minimum of 2 hours per day, 4 days a week with them and is willing to comply with all study procedures
APOLLOE4 Alzheimer’s Study - The APOLLO Study
Our team of medical professionals is evaluating an investigational drug that is designed to slow the progression of Alzheimer’s Disease. The study drug, ALZ-801, is a tablet that is taken twice daily. It has been well tolerated in earlier studies and may be a convenient option for Alzheimer’s patients and their families. Participating in this study, will help advance the treatment of Alzheimer’s disease.
This study might be right for you if you are:
- Experiencing memory loss due to Alzheimer’s disease (the study doctor will be able to confirm if you have Alzheimer’s)
- Between 50 and 80 years of age
- Positive for the APOE4/4 gene (genetic testing provided at no cost)
- Accompanied by a caregiver or study partner willing to attend study visits and participate with you
CuraSen - Alzheimer's and Parkinson's Study
This research study is evaluating an investigational drug combination, CST-2032 combined with CST-107 (nadolol), as a possible treatment for cognitive impairment due to Alzheimer’s disease (AD) or Parkinson’s disease (PD) with rapid eye movement (REM) sleep behavior disorder. CuraSen Therapeutics, Inc. is sponsoring this research study.
This study might be right for you if you are:
- Diagnosed with cognitive impairment due to Alzheimer's disease
- Diagnosed with cognitive impairment due to Parkinson's disease
- Diagnosed with REM due to Parkinson's disease
Alzheimer's Disease - The SKYLINE Study
Alzheimer’s is linked to the build-up of an abnormal protein in the brain called amyloid beta. Early on, this process doesn’t cause any obvious symptoms. But later, cognitive problems such as memory loss may emerge. The question is, could targeting amyloid beta prevent this?
This study might be right for you if you are:
- Be 60–80 years old
- Not be experiencing any memory or thought-processing problems
- Not be diagnosed with Mild Cognitive Impairment (MCI), Alzheimer’s or dementia
- Be interested in learning about your risk of developing Alzheimer’s
- Able to join with a study partner Item
Novartis - Multiple Sclerosis and Covid Study
f you are between the ages of 18 and 55 and have been diagnosed with relapsing multiple sclerosis
(MS), you may quality for a voluntary research study.
This study might be right for you if you are:
- Be between the ages of 18 and 55
- Have been diagnosed with relapsing MS
- Are starting or currently being treated with ofatumumab or on interferon or glatiramer acetate for MS
Multiple Sclerosis - The ENSURE Study
The purpose of the ENSURE Study is to investigate how safe and effective the study drug is in helping treat people with Relapsing Multiple Sclerosis by reducing relapses.
This study might be right for you if you are:
- Between the age of 18 and 55
- Diagnosed with RMS
- Having a history of active disease, meaning at least 2 relapses in the last 2 years or 1 relapse in the last year
Parkinson's Disease - The ORCHESTRA Study
The Orchestra Study is a clinical research study for people with early-stage Parkinson’s disease. The aim of the study is to see whether the investigational medication known as UCB0599 can slow Parkinson’s disease progression.
This study might be right for you if you are:
- Diagnosed with Parkinson’s Disease by a neurologist according to the 2015 movement Disorder Society within 2 years of baseline visit
- Age 40 to 75 inclusive at time of signing
- Having presence of bradykinesia AND at least ONE of the following: Muscular rigidity, or resting tremor
PrecMed Parkinson’s Study
The purpose of this medical study is to collect biological samples from subjects with Parkinson’s disease. The samples may contain substances that the researchers will be able to analyze to study their genetic, protein, and chemical composition. The study will look at blood and cerebrospinal fluid differences associated with Parkinson’s disease or with other aspects of the illness, such as response to medication and side effects. The cells from your blood may be retained as cell lines grown from your blood to be used in the future. The sample may assist in the development of a new drug treatment or a new diagnostic test for Parkinson’s disease. Your samples will be kept indefinitely by the sponsor.
PrecMed Alzheimer’s Study
The purpose of this medical study is to collect biological samples from subjects with Alzheimer’s disease. The samples may contain substances that the researchers will be able to analyze to study their genetic, protein, and chemical composition. The study will look at blood and cerebrospinal fluid differences associated with Alzheimer’s disease or with other aspects of the illness, such as response to medication and side effects. The cells from your blood may be retained as cell lines grown from your blood to be used in the future. The sample may assist in the development of a new drug treatment or a new diagnostic test for Alzheimer’s disease. Your samples will be kept indefinitely by the sponsor.
PrecMed Multiple Sclerosis Study
The purpose of this medical study is to collect biological samples from subjects with Multiple Sclerosis. The samples may contain substances that the researchers will be able to analyze to study their genetic, protein, and chemical composition. The study will look at blood and cerebrospinal fluid differences associated with Multiple Sclerosis or with other aspects of the illness, such as response to medication and side effects. The cells from your blood may be retained as cell lines grown from your blood to be used in the future. The sample may assist in the development of a new drug treatment or a new diagnostic test for Multiple Sclerosis. Your samples will be kept indefinitely by the sponsor.
The SOSTOS Multiple Sclerosis Study
The purpose of this study is to find out if patients who have not had a relapse in the past year would benefit from switching to ofatumumab compared to continuing their current MS treatment. This study will also find out if having an elevated Neurofilament light (NfL) level can predict a greater benefit from switching to ofatumumab compared to continuing current treatment. NfL is a biomarker that may be an indicator of damage in a wide variety of neurological disorders.